Note 9 - Segment Information and Disaggregated Revenue

6 Months Ended

Dec. 31, 2024

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

Note 9. Segment Information and Disaggregated Revenue

The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company’s operating segments.

The Company has divided its operations into two reportable segments as follows: Contract Manufacturing, and Other Nutraceutical Businesses. International sales, concentrated primarily in Europe, for the three months ended December 31, 2024 and 2023 were $2,355 and $1,656, respectively and for the six months ended December 31,2024 and 2023 were $4,540 and $3,265, respectively.

Financial information relating to the three months ended December 31, 2024 and 2023 operations by business segment and disaggregated revenues was as follows:

		Sales, Net						Segment
		U.S.		International				Gross				Capital
		Customers		Customers		Total		Profit (loss)		Depreciation		Expenditures
Contract Manufacturing	2024	$	9,315	$	2,355	$	11,670	$	797	$	83	$	29
	2023		9,424		1,629		11,053		500		78		24
Other Nutraceutical Businesses	2024		944		-		944		374		-		-
	2023		429		27		456		20		-		-
Total Company	2024		10,259		2,355		12,614		1,171		83		29
	2023		9,853		1,656		11,509		520		78		24

Financial information relating to the six months ended December 31, 2024 and 2023 operations by business segment and disaggregated revenues was as follows:

		Sales, Net						Segment
		U.S.		International				Gross				Capital
		Customers		Customers		Total		Profit		Depreciation		Expenditures
Contract Manufacturing	2024	$	20,103	$	4,540	$	24,643	$	1,975	$	170	$	85
	2023		20,252		3,238		23,490		1,313		154		59
Other Nutraceutical Businesses	2024		1,588		-		1,588		567		1		-
	2023		907		27		934		39		1		3
Total Company	2024		21,691		4,540		26,231		2,542		171		85
	2023		21,159		3,265		24,424		1,352		155		62

	Total Assets as of
	December 31,		June 30,
	2024		2024
Contract Manufacturing	$	19,572	$	20,830
Other Nutraceutical Businesses		6,089		5,377
Total Company	$	25,661	$	26,207